When combined with cyclophosphamide and trastuzumab for neoadjuvant therapy in HER2-positive BC, docetaxel has shown a high pCR rate, suggesting that this combination regimen could be an effective option for preoperative treatment of HER2-positive BC (65). The gene discussed is ERBB2; the disease is breast cancer.